GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Harpoon Therapeutics
Harpoon, an oncology company, had a historical timeline that reflected the potential of its immunotherapeutic developments based on T-cell enhancers. Its history culminated in its acquisition by Merck in 2024.
Share prices of companies in the market segment - Oncology immuno-therapy
Harpoon Therapeutics is an oncology company developing a new class of immunotherapeutic drugs based on T-cell activators (engagers). We've categorized it as "Immuno-Oncology." The chart below shows how investors evaluate innovative drug discovery platforms.
Broad Market Index - GURU.Markets
Harpoon Therapeutics is an oncology company developing a new class of immunotherapeutic drugs based on T-cell activators. As an innovator in this field, it is included in our GURU.Markets index. The chart below shows the overall market trend. See how Harpoon shares compare to sentiment in the biotech sector.
Change in the price of a company, segment, and market as a whole per day
HARP - Daily change in the company's share price Harpoon Therapeutics
For Harpoon Therapeutics, Inc., an immuno-oncology company, daily price change is a measure of extreme volatility. It reflects the market's reaction to clinical trial data and is a critical parameter in risk assessment formulas.
Daily change in the price of a set of shares in a market segment - Oncology immuno-therapy
Before its acquisition by Merck, Harpoon Therapeutics was developing a new class of immuno-oncology drugs. Its history exemplifies the strategy of large pharmaceutical companies to acquire innovative technologies. The chart below illustrates the volatility of the biotech sector, which makes such acquisitions common.
Daily change in the price of a broad market stock, index - GURU.Markets
Harpoon Therapeutics is a biotech company developing cancer immunotherapy drugs. Its shares are buoyed by anticipation of clinical trial results. These sharp, event-driven movements are part of a complex mosaic of stock market volatility.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Harpoon Therapeutics
For Harpoon Therapeutics, year-over-year performance is a story about its T-cell enhancer platform. Its market cap change over the past 12 months reflects progress in its clinical trials, as well as its recent acquisition by Merck, which provided fundamental validation of its scientific platform's potential in immuno-oncology.
Annual dynamics of market capitalization of the market segment - Oncology immuno-therapy
Harpoon, a biotech company, developed immunotherapy. Its acquisition by Merck was a recognition of its scientific platform. Its past performance reflected both the risks of clinical trials and the potential for breakthroughs, typical of this sector.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Harpoon Therapeutics, a biopharmaceutical company developing T-cell activators for cancer immunotherapy, is another oncology innovator. Its year-over-year market capitalization dynamics depend entirely on clinical data, which can either confirm or refute the potential of its unique platform.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Harpoon Therapeutics
Harpoon is an oncology company with a unique platform. Its monthly performance was entirely tied to clinical trial results. Volatility on the chart culminated in a sharp rise after the announcement of its acquisition by Merck, which determined its final price.
Monthly dynamics of market capitalization of the market segment - Oncology immuno-therapy
Harpoon Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing a new class of T-cell immuno-oncology therapies. The dynamics of its sector, shown in the chart, reflect the risks of R&D. Against this backdrop, one can assess the progress of its proprietary TriTAC platform, which targets cancer cells, in clinical trials.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Harpoon Therapeutics is an immuno-oncology company whose stock is immersed in the world of biotech news. Its dynamics are driven by successes in clinical trials. The chart shows that the company's monthly fluctuations barely correlate with the overall market, but are a reaction to company-specific events.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Harpoon Therapeutics
Harpoon Therapeutics, a biotech developing immuno-oncology drugs, exhibits high volatility. Weekly stock performance is driven by news about clinical trials and partnerships, reflecting the risks and potential of its unique platform.
Weekly dynamics of market capitalization of the market segment - Oncology immuno-therapy
Harpoon Therapeutics shares, like the entire oncology biotech sector, are driven by sector-wide news and sentiment. Breakthroughs in immunotherapy or changes in FDA policy could boost the entire industry. The chart shows how the company stacks up against this high-risk segment.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Harpoon Therapeutics is a clinical-stage biotech company. Its shares exist in a world of their own, where research data is king. The chart clearly demonstrates that HARP's performance is largely uncorrelated with the market.
Market capitalization of the company, segment and market as a whole
HARP - Market capitalization of the company Harpoon Therapeutics
The Harpoon Therapeutics chart is a financial map of innovation in immuno-oncology. The market cap of this company, which develops T-cell activators, reflects its belief in its ability to "unleash" the immune system against cancer. Its dynamics are a barometer of its clinical data and strategic partnerships, which shape the future of its scientific platform.
HARP - Share of the company's market capitalization Harpoon Therapeutics within the market segment - Oncology immuno-therapy
Harpoon Therapeutics specializes in developing a new class of immuno-oncology drugs. The company's market capitalization in the biotech sector reflects the potential of its unique T-cell enhancer technology. Harpoon's market weight reflects the market's assessment of its chances of success in the fight against difficult-to-treat cancers.
Market capitalization of the market segment - Oncology immuno-therapy
Harpoon Therapeutics is developing a new class of T-cell-based immunotherapy drugs. The chart below shows the overall market capitalization of the entire oncology sector. Its dynamics reflect investors' hopes that these new approaches will help defeat cancer.
Market capitalization of all companies included in a broad market index - GURU.Markets
Harpoon Therapeutics is an oncology company developing a new generation of T-cell enhancers. Its market cap represents a financial bet on an innovative approach to immunotherapy. Its value reflects both the potential of its scientific platform and the risks of clinical trials.
Book value capitalization of the company, segment and market as a whole
HARP - Book value capitalization of the company Harpoon Therapeutics
For Harpoon Therapeutics, an oncology company, book value represents its R&D capital. The chart below shows its financial resources for developing innovative T-cell enhancers. This level is an indicator of its ability to fund its research programs.
HARP - Share of the company's book capitalization Harpoon Therapeutics within the market segment - Oncology immuno-therapy
Harpoon Therapeutics is a clinical-stage biotech company developing immunotherapy. Its value lies in its scientific platform. Its tangible asset share will be minimal, which is typical for R&D companies whose primary capital is intellectual property.
Market segment balance sheet capitalization - Oncology immuno-therapy
Below you can see the overall book value of the biotech sector. Compared to this, Harpoon, which develops T-cell activators, looks like a "lightweight." Its value lies in its scientific platform and patents, not in its large manufacturing facilities, which is typical for a company focused on R&D.
Book value of all companies included in the broad market index - GURU.Markets
Harpoon Therapeutics is developing a new class of immuno-oncology drugs (trispecific antibodies). The company's assets are patents and a scientific platform. The company's balance sheet is the value of the "trident" they are creating to unleash the immune system on cancer cells with triple force.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Harpoon Therapeutics
Harpoon's balance sheet is its cash and scientific platform. Its market cap is a bet on its trispecific antibody technology. The MvsBCap_Co chart shows how investors value this "dream" of a new class of cancer drugs.
Market to book capitalization ratio in a market segment - Oncology immuno-therapy
Harpoon Therapeutics was developing a new class of immuno-oncology drugs. Its value lay in its scientific platform. The chart showed a speculative valuation of its technology, reflecting investors' hopes for a new approach to cancer treatment.
Market to book capitalization ratio for the market as a whole
Harpoon Therapeutics specializes in immuno-oncology drugs. For such companies, market capitalization reflects investor faith in their scientific approach. This metric demonstrates how the market values the potential of their T-cell activators, pricing in the hope of creating a new generation of cancer drugs, which is far from the current balance.
Debts of the company, segment and market as a whole
HARP - Company debts Harpoon Therapeutics
For Harpoon Therapeutics, a company developing a new class of immuno-oncology drugs, debt is a source of funding for research. This chart shows how the company is raising capital to conduct clinical trials of its tri-specific antibodies. In the biotech world, debt is a vital resource for testing cutting-edge concepts.
Market segment debts - Oncology immuno-therapy
Harpoon Therapeutics is developing a new class of immuno-oncology drugs called trispecific antibodies. This chart shows how the clinical-stage biotech is managing its capital to advance its innovative, yet risky, scientific platform in one of the most competitive fields of medicine.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Harpoon Therapeutics
Harpoon Therapeutics is a biotech company focused on immuno-oncology. Its financial model is built on investing in science. This chart shows its debt level, which is a measure of risk: the higher the debt, the more dependent the company is on positive clinical trial results for its survival and future success.
Market segment debt to market segment book capitalization - Oncology immuno-therapy
Harpoon Therapeutics is developing a new class of immuno-oncology drugs called T-cell enhancers. This is a cutting-edge but risky area of research. The chart shows how the company's debt load for funding clinical trials compares to the market capitalization and risk profile of the overall biotech sector.
Debt to book value of all companies in the market
Harpoon Therapeutics (HARP) is an immuno-oncology company developing a new class of T-cell activators to fight cancer. This is a cutting-edge, yet capital-intensive, field. This chart shows the overall level of debt in the economy. It clearly demonstrates why biotech companies in the R&D stage use virtually no debt in their capital structure.
P/E of the company, segment and market as a whole
P/E - Harpoon Therapeutics
This metric for Harpoon Therapeutics, a company developing a new class of immunotherapeutic drugs (tri-specific antibodies), is a bet on a scientific breakthrough. There is no P/E ratio. The company's valuation depends on the success of its platform in clinical trials and the interest of major pharmaceutical companies.
P/E of the market segment - Oncology immuno-therapy
This chart shows the average P/E ratio for biotech companies. For Harpoon, which is developing a new class of immunotherapeutic drugs, it serves as a backdrop. It reflects the overall level of optimism in immuno-oncology, providing context for Harpoon's valuation, which is a bet on its unique scientific platform.
P/E of the market as a whole
Harpoon Therapeutics is developing a new class of immuno-oncology drugs called TriTACs, which direct T cells to destroy cancer cells. The company was acquired by Merck. This chart shows the biotech sentiment. It helps us understand how an acquisition by a major pharmaceutical company validates the value of a technology platform and how this impacts the valuation of other similar biotech companies.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Harpoon Therapeutics
Harpoon Therapeutics is developing a new class of immuno-oncology drugs called T-cell enhancers. For a clinical-stage company, this chart reflects analysts' confidence in its scientific platform. It shows the market's expected future profit margin, based on positive clinical trial results.
%20P%2FE%20Harpoon%20Therapeutics&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Harpoon-Therapeutics&v=1772680530394 "Chart of the company's future (projected) P/E Harpoon Therapeutics")
Future (projected) P/E of the market segment - Oncology immuno-therapy
Harpoon Therapeutics is developing a new class of immuno-oncology drugs called TriTACs to combat cancer. This chart shows average expectations for the biotech sector. HARP's position may indicate the extent to which investors believe in its unique technology platform and the potential of its developments to create effective treatments.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Oncology%20immuno-therapy&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Oncology-immuno-therapy&v=1772680530397 "Future (projected) P/E graph of the market segment - Oncology immuno-therapy")
Future (projected) P/E of the market as a whole
Harpoon Therapeutics is an immuno-oncology company. Its valuation depends almost entirely on the success of its scientific platforms and clinical data. Overall investor sentiment on this chart influences the stock's context, but for Harpoon, lab news is crucial.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772680530442 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Harpoon Therapeutics
Harpoon Therapeutics is developing a new class of immuno-oncology drugs called TriTACs, which direct the body's own T cells to destroy cancerous tumors. This chart shows innovations in the fight against cancer. The losses reflect clinical trial costs, while future profits depend on the success of this promising technology.
Profit of companies in the market segment - Oncology immuno-therapy
Harpoon Therapeutics is developing a new class of immunotherapeutic drugs called TriTACs for the treatment of cancer. Profitability in the immuno-oncology sector, as this chart shows, depends on scientific innovation. The HARP platform aims to create safer and more effective drugs that activate a patient's T cells to destroy tumors.
Overall market profit
Harpoon Therapeutics, a biopharmaceutical company developing innovative cancer immunotherapies, relies on science, not economics. Its future is determined by the results of clinical trials. However, the market situation, which this graph indirectly reflects, is critical for attracting the funding needed to bring cutting-edge drugs to market.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Harpoon Therapeutics
Harpoon Therapeutics is developing a new class of immuno-oncology drugs. This chart reflects analyst forecasts, which essentially assess the scientific potential of its unique platform. The trend reflects the market's confidence in the success of its clinical programs.
%20profit%20of%20the%20company%20Harpoon%20Therapeutics&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Harpoon-Therapeutics&v=1772680530599 "Graph of future (projected) profit of the company Harpoon Therapeutics")
Future (predicted) profit of companies in the market segment - Oncology immuno-therapy
Harpoon Therapeutics is a biotech company developing a new class of immuno-oncology drugs called TriTACs, which direct the body's own T cells to destroy cancer cells. This chart shows the revenue forecast for the immuno-oncology sector, reflecting expectations for the emergence of new platforms for activating the immune system against cancer.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Oncology%20immuno-therapy&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Oncology-immuno-therapy&v=1772680530622 "Graph of future (predicted) profits of companies in a market segment - Oncology immuno-therapy")
Future (predicted) profit of the market as a whole
Harpoon Therapeutics is an oncology company developing a new class of immunotherapeutic drugs. Its valuation depends on the success of its clinical programs. The overall economic outlook is important for assessing the investment climate. During recessions, raising the capital needed for expensive research becomes more challenging for such companies.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772680530638 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Harpoon Therapeutics
Harpoon Therapeutics was developing a new class of immuno-oncology drugs called T-cell engagers. Without commercial revenue, its valuation on this chart was based on the potential of its scientific platform. Investors were betting that its unique approach to activating the immune system to fight cancer would prove successful in the clinic.
P/S market segment - Oncology immuno-therapy
Harpoon Therapeutics is developing a new class of immuno-oncology drugs called TriTACs, which direct the body's T cells to destroy cancer cells. The chart shows the average revenue estimate for the biotech company, helping to gauge investor confidence in the potential of its unique scientific platform.
P/S of the market as a whole
Harpoon Therapeutics is developing a new class of immunotherapeutic drugs (trispecific antibodies) for the treatment of cancer. This represents a cutting-edge technology in oncology. The graph of average market revenue estimates clearly demonstrates that the company's market capitalization is based not on current revenue, but on the expected future success of its scientific platform.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Harpoon Therapeutics
Harpoon Therapeutics is an immuno-oncology company developing a new class of T-cell-targeted therapies. The chart shows the market's forward valuation of its research, correlating the company's value with the potential future sales of its innovative therapies, which redirect the immune system to fight cancer.
%20P%2FS%20Harpoon%20Therapeutics&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Harpoon-Therapeutics&v=1772680530896 "The graph of the company's future (projected) P/S Harpoon Therapeutics")
Future (projected) P/S of the market segment - Oncology immuno-therapy
Harpoon Therapeutics is developing a new class of immuno-oncology drugs called TriTACs, which direct T cells to destroy cancer cells. The average future revenue estimates for companies in its core business are shown here. This helps assess the market's perception of Harpoon's platform and its cancer immunotherapy candidates.
%20P%2FS%20market%20segment%20graph%20-%20Oncology%20immuno-therapy&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Oncology-immuno-therapy&v=1772680530949 "Future (projected) P/S market segment graph - Oncology immuno-therapy")
Future (projected) P/S of the market as a whole
Harpoon Therapeutics was developing a new class of immuno-oncology therapies. Its future depended on the success of clinical trials. This indicator of overall revenue expectations was of little significance to the company. HARP's entire value lay in its scientific platform and the potential to create breakthrough cancer treatments.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772680530992 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Harpoon Therapeutics
Harpoon Therapeutics is a clinical-stage biotech developing a new class of immuno-oncology drugs. Because its products are in development, the company typically does not generate sales revenue. Any revenue shown in this chart likely comes from upfront payments from strategic partners.
Sales of companies in the market segment - Oncology immuno-therapy
Harpoon Therapeutics is developing a new class of immuno-oncology drugs called T-cell energizers. These drugs direct the patient's own immune cells to destroy cancer cells. This chart shows the total revenue in the immuno-oncology sector, allowing us to assess the rapid growth and commercialization of this promising market.
Overall market sales
Harpoon Therapeutics is a biotech company developing immunotherapy for cancer treatment. Its development depends on successful clinical trials. The overall economic situation, reflected in this chart, influences the level of investment in the biotech sector and funding for advanced treatments.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Harpoon Therapeutics
Harpoon Therapeutics is developing a new class of immuno-oncology drugs called TriTACs, which recruit T cells to destroy cancer cells. The company's future depends on the success of this platform in the clinic. This chart visualizes market expectations regarding the potential of this innovative technology.
%20sales%20of%20the%20company%20Harpoon%20Therapeutics&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Harpoon-Therapeutics&v=1772680531096 "Schedule of future (projected) sales of the company Harpoon Therapeutics")
Future (projected) sales of companies in the market segment - Oncology immuno-therapy
Harpoon Therapeutics is developing a new class of immuno-oncology drugs called trispecific antibodies, which direct immune cells to destroy tumors. The chart shows forecasts for the immuno-oncology sector. This is a cutting-edge scientific platform, and the company's future depends on the results of clinical trials.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Oncology%20immuno-therapy&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Oncology-immuno-therapy&v=1772680531125 "Schedule of future (projected) sales of companies in the market segment - Oncology immuno-therapy")
Future (projected) sales of the market as a whole
Harpoon Therapeutics is developing a new class of immuno-oncology drugs called TriTACs. The company's success depends on the results of clinical trials. This schedule, reflecting the overall investment climate, influences the willingness of investors and large pharmaceutical companies to invest in cutting-edge, but not yet fully proven, oncology technologies.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772680531171 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Harpoon Therapeutics
Harpoon Therapeutics is developing a new class of immuno-oncology drugs (trispecific antibodies) to fight cancer. The company is in the high-cost clinical trials phase. This chart illustrates the financial path to developing innovative drugs that could be a breakthrough in cancer treatment.
Market segment marginality - Oncology immuno-therapy
Harpoon Therapeutics is developing a new class of immunotherapeutic drugs, T-cell engagers, for the treatment of oncology. This chart shows the average profitability in the pharmaceutical industry. The company's innovative platform gives it the potential to create highly effective drugs and achieve profitability significantly above the industry average in the future.
Market marginality as a whole
Harpoon Therapeutics is developing a new class of immunotherapeutic drugs (trispecific antibodies) for the treatment of cancer. The company is in clinical trials. This total revenue chart clearly illustrates the gap between today's revenue-generating businesses and the research-intensive companies investing in breakthrough treatments.
Employees in the company, segment and market as a whole
Number of employees in the company Harpoon Therapeutics
Harpoon Therapeutics is a biotech company developing a new class of immuno-oncology drugs. Its main assets are its scientific platform and its people. This chart shows the size of the research team working on developing innovative drugs that can harness the immune system to fight cancer.
Share of the company's employees Harpoon Therapeutics within the market segment - Oncology immuno-therapy
Harpoon Therapeutics pioneered the development of a new class of immuno-oncology drugs called T-cell energizers. During clinical trials, its team comprised leading scientists in the field. This graph reflects its status as an innovation center, where a small but highly skilled team was able to create a technology that attracted the attention of big pharma.
Number of employees in the market segment - Oncology immuno-therapy
Harpoon Therapeutics, Inc. is an immuno-oncology company developing a new class of T-cell activators. The growth of its research team, which can be seen in the graph, is a leading indicator. This increase in staffing suggests that its platform is generating new promising drug candidates for cancer treatment.
Number of employees in the market as a whole
Harpoon Therapeutics, acquired by Merck, specialized in developing T-cell enhancers for cancer immunotherapy. The growth of its small but highly skilled team of scientists in this chart demonstrated progress in developing the innovative platform. The expansion reflected confidence in the potential of its technology, which ultimately led to the acquisition.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Harpoon Therapeutics (HARP)
Harpoon Therapeutics develops immuno-oncology drugs. As with most biotech companies, the company's value is concentrated in its patents and clinical trial results. This chart shows how the market values the company's intellectual property. This represents the "innovation premium" that investors are willing to pay per employee driving scientific progress.
%20of%20the%20company%20Harpoon%20Therapeutics%20(HARP)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Harpoon-Therapeutics-HARP&v=1772680531314 "Chart of market capitalization per employee (in thousands of dollars) of the company Harpoon Therapeutics (HARP)")
Market capitalization per employee (in thousands of dollars) in the market segment - Oncology immuno-therapy
Harpoon Therapeutics is developing a new class of immuno-oncology drugs called T-cell engagers. Its market cap is based on the potential of this innovative technology. This chart illustrates investors' high valuation of the company's scientific potential and its TriTAC platform, calculated per research team member.
%20by%20market%20segment%20-%20Oncology%20immuno-therapy&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Oncology-immuno-therapy&v=1772680531344 "Market capitalization per employee (in thousands of dollars) by market segment - Oncology immuno-therapy")
Market capitalization per employee (in thousands of dollars) for the overall market
Harpoon Therapeutics is developing a new class of immunotherapeutic drugs (trispecific antibodies) for the treatment of cancer. The chart shows the valuation of the scientific platform. It reflects how the market values their unique approach to fighting tumors, where the contribution of a small team of scientists can lead to the creation of powerful new drugs.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772680531366 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Harpoon Therapeutics (HARP)
Harpoon (recently acquired by Merck) is a biotech company developing T-cell enhancers (TriTACs) for cancer treatment. The company was unprofitable. This chart reflects the burn rate of its R&D budget. Every employee is a scientist who worked on the platform acquired by the giant.
%20Chart%20Harpoon%20Therapeutics%20(HARP)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Harpoon-Therapeutics-HARP&v=1772680531389 "Company Profit Per Employee (in thousands of dollars) Chart Harpoon Therapeutics (HARP)")
Profit per employee (in thousands of dollars) in the market segment - Oncology immuno-therapy
Harpoon Therapeutics is developing a new class of immuno-oncology drugs called T-cell enhancers (TriTACs). This graph shows the loss per employee during clinical trials. It serves as a benchmark for assessing how intensively the company is investing in its unique scientific platform compared to other biotechs working in the field of immunotherapy.
%20in%20the%20market%20segment%20-%20Oncology%20immuno-therapy&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Oncology-immuno-therapy&v=1772680531411 "Chart of profit per employee (in thousands of dollars) in the market segment - Oncology immuno-therapy")
Profit per employee (in thousands of dollars) for the market as a whole
Harpoon Therapeutics is a biotech R&D company developing a platform of "tri-specific" antibodies (T-cell engagers) to combat cancer. The company has no commercial products. This chart shows a negative profit (loss) per scientist, which is typical for a biotech company working on complex immunotherapy platforms.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772680531472 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Harpoon Therapeutics (HARP)
Harpoon Therapeutics develops innovative immuno-oncology drugs. For a clinical-stage biotech, this graph is an indicator of commercial progress. Increased revenue per employee is typically driven by upfront payments from partners, confirming the value of its scientific platform.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Harpoon-Therapeutics-HARP&v=1772680531515 "Sales chart per company employee Harpoon Therapeutics (HARP)")
Sales per employee in the market segment - Oncology immuno-therapy
Harpoon (HARP) is a clinical-stage biotech company (acquired by Merck) developing a new class of immunotherapy (T-cell engagers). The company has no approved products or commercial revenue. This chart doesn't reflect their value. Staff productivity would be zero here, as the entire staff is focused on R&D.
Sales per employee for the market as a whole
Harpoon Therapeutics is an immuno-oncology company. Like many development-stage biotechs, this metric reflects ongoing investment in research. A team of highly qualified researchers is working on future drugs. This graph is important for tracking the transition to commercialization, when revenue from approved drugs begins to cover the cost of R&D personnel.
Short shares by company, segment and market as a whole
Shares shorted by company Harpoon Therapeutics (HARP)
Harpoon (HARP) is a biotech company developing a new class of immunotherapy (T-cell engagers) for cancer treatment. Their TriTAC platform is designed to direct a patient's T cells to the tumor. This chart shows bearish bets. Bears doubt the safety and effectiveness of this complex technology.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Harpoon-Therapeutics-HARP&v=1772680531571 "Short Shares Chart for the Company Harpoon Therapeutics (HARP)")
Shares shorted by market segment - Oncology immuno-therapy
Harpoon Therapeutics is a biopharmaceutical company developing a new class of immunotherapy (T-cell stimulants) for the treatment of oncology diseases. This chart shows the total volume of short positions across the entire oncology biotech sector. It serves as a barometer of sentiment: if investors are shorting the sector, they doubt the success of new platforms or expect failure in clinical trials.
Shares shorted by the overall market
Harpoon Therapeutics develops new cancer immunotherapies—a critical but capital-intensive endeavor. Like many biotechs without stable revenue, it relies on external funding. This indicator of market pessimism is a strong headwind, as fear typically closes the funding window for companies far from profitable.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Harpoon Therapeutics (HARP)
Harpoon Therapeutics developed innovative T-cell activators (TriTAC) for immuno-oncology. This chart is another biotech M&A story. Investor interest has peaked and plateaued. This reflects the company's acquisition by the giant Merck, which valued its platform as strategically important for its oncology portfolio.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Harpoon-Therapeutics-HARP&v=1772680531697 "RSI 14 indicator chart for the company's stock Harpoon Therapeutics (HARP)")
RSI 14 Market Segment - Oncology immuno-therapy
Harpoon Therapeutics is a biotech company, an immune system engineer. Their TriTAC platform created "three-armed" antibodies (T-cell engagers) to attack cancer (acquired by Merck). The "Oncology immunotherapy" sector thrives on news. RSI_14_Seg shows the "temperature" of this entire segment. It helps us understand: was Harpoon's acquisition a matter of their technology or a general "overheating" in biotech?
RSI 14 for the overall market
For Harpoon Therapeutics, a biotech in R&D, this chart is a lifeline showing capital availability. During periods of market euphoria, investors are willing to "buy the dream" and fund breakthrough but risky research. When the market panics, the money supply is shut off, and cash-burning companies face a liquidity crisis.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast HARP (Harpoon Therapeutics)
Harpoon Therapeutics (acquired by Merck) is a biotech company that developed the TriTAC platform for developing T-cell enhancers for cancer treatment. This chart shows the average Wall Street forecast. Analysts' estimates were based on clinical data for its candidates and the strategic value of its platform to pharma giants.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-HARP-Harpoon-Therapeutics&v=1772680531870 "A chart showing analyst consensus forecasts for the expected stock price. HARP (Harpoon Therapeutics)")
The difference between the consensus estimate and the actual stock price HARP (Harpoon Therapeutics)
Harpoon is a "harpoon" for cancer. The biotech company developed a platform of "T-cell engagers" (TriTAC)—"smart" molecules that target tumors with the immune system. This chart illustrates the analyst community's opinion on the company's future. It measures the distance between the stock price and the target, which is now tied to the acquisition price of the giant Merck.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-HARP-Harpoon-Therapeutics&v=1772680531946 "A chart showing the difference between the consensus forecast and the actual stock price. HARP (Harpoon Therapeutics)")
Analyst consensus forecast for stock prices by market segment - Oncology immuno-therapy
Harpoon (HARP) is a biotech company that has developed "bispecific" antibodies (TriTACs) that direct immune T cells to tumors. This chart shows general expectations for the immunotherapy sector. It reflects whether experts believe in R&D breakthroughs in cancer treatment or consider the sector overheated.
Analysts' consensus forecast for the overall market share price
Harpoon Therapeutics (HARP) is a biopharmaceutical company working at the forefront of immuno-oncology. They developed "T-cell energizers" (the TriTAC platform) to fight cancer. This chart shows the overall risk appetite in the market. It is an indicator of the "open" or "closed" funding window for speculative biotechs.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Harpoon Therapeutics
Harpoon is a harpoon for cancer. They're a biotech R&D company (in immuno-oncology). Their signature feature is their TriTAC R&D platform: tiny adapters (not large CAR-T cells) that grab a T cell (immunity) and attract it to a cancer cell. This chart is a pure R&D barometer. It doesn't reflect revenue, but a speculative valuation of their (very risky) pipeline.
AKIMA Market Segment Index - Oncology immuno-therapy
Harpoon (HARP) is immuno-oncology with a harpoon. Their technology (TriTAC) creates T-cell energizers—molecules that grab immune cells and drag them to the tumor. This is precision R&D. This chart compares their composite index to the sector average.
The AKIM Index for the overall market
Harpoon Therapeutics is an immuno-oncology company developing T-cell enhancers. It was acquired by Merck. This chart, which reflects the market average, provides a macro backdrop. It helps assess how this scientific platform, which has attracted big pharma, compares to overall economic trends.
